CCS Integrated Cases

CCS case: acute shortness of breath with bilateral crackles

Clinical Overview and When to Suspect Acute Pulmonary Edema

— The case tests your ability to stabilize first, diagnose in parallel, and titrate therapy on a clock (q15min vitals, q1h reassessment)

— Wrong-bucket thinking (treating ARDS as ADHF with aggressive diuresis, or treating ADHF as pneumonia with fluids) is the classic CCS trap

— Sudden or subacute dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND)

— Bilateral basilar crackles ± wheeze ("cardiac asthma"), S3 gallop, elevated JVP, pink frothy sputum in severe cases

— Triggers: dietary indigestion, medication nonadherence, uncontrolled HTN (flash pulmonary edema), new AFib with RVR, ACS, renal failure

— Fever, productive sputum, focal consolidation → pneumonia/ARDS

— Recent aspiration event, altered mental status → aspiration pneumonitis

— Transfusion within 6h → TRALI

— Diffuse alveolar hemorrhage, hemoptysis → vasculitis

— Older adult with HTN, CAD, DM, prior MI, AFib → cardiogenic likely

— Young patient, no cardiac history, sepsis features → ARDS likely

— Pregnancy near term/postpartum → peripartum cardiomyopathy or preeclampsia-related pulmonary edema

CCS pearl: On arrival to the ED, your first three actions in this case should be (1) place on continuous pulse ox + telemetry, (2) supplemental O2 titrated to SpO2 ≥92%, (3) IV access × 2 — order these before labs. CCS rewards parallel ordering: stabilization, diagnostics, and empiric therapy can all be entered in the same time block. Do not wait for BNP to start a loop diuretic if the clinical picture is convincing.

Clinical scenario: Adult presenting to ED with acute dyspnea, orthopnea, and bilateral inspiratory crackles is the prototype CCS case for acute decompensated heart failure (ADHF) with cardiogenic pulmonary edema — but the differential is broad and the early orders must hedge.

Why this matters on CCS:

When to suspect cardiogenic pulmonary edema:

When to suspect noncardiogenic causes despite bilateral crackles:

Epidemiology cues:

Presentation Patterns and Key History

— 68-year-old with HFrEF (EF 30%), HTN, CKD presents with 2 days of progressive dyspnea, 3-pillow orthopnea, lower-extremity swelling, 6-lb weight gain over a week, ran out of furosemide

— Or: sudden severe dyspnea waking patient from sleep (PND) with BP 210/120 — hypertensive flash pulmonary edema

— Onset: sudden (flash edema, PE, MI) vs gradual (volume overload, pneumonia)

— Orthopnea, PND, pillows used at night

— Chest pain → ACS-driven HF; always obtain ECG in <10 min

— Palpitations → new AFib precipitating decompensation

— Fever, cough, sputum → pneumonia

— Hemoptysis → PE, mitral stenosis, DAH

— Medication adherence (furosemide, ACEi, β-blocker), recent dose changes

— Dietary indiscretion (salty meal, holiday weekend)

— Recent IV contrast, transfusion, NSAID use

— Substance use: cocaine, methamphetamine → catecholamine-driven flash edema

— Prior MI, CABG, valvular disease (especially MR, AS)

— Dialysis schedule — missed HD is a top precipitant

— Sleep apnea (OSA worsens nocturnal pulmonary edema)

— Pregnancy status in any woman 12–50

— Minutes to 1 hour: flash edema, papillary muscle rupture, acute MR, PE, anaphylaxis

— Hours to days: classic ADHF volume overload

— Days to weeks with fevers: pneumonia, subacute endocarditis with HF

Board pearl: PND and orthopnea are the most specific symptoms for HF (LR+ ~2–6); their absence does not rule out HF but their presence in an older adult with crackles essentially clinches cardiogenic etiology pending objective data.

Key distinction: Bilateral crackles + fever + productive cough ≠ ADHF reflexively — order CXR and procalcitonin/lactate before committing to a diuretic-only path; mixed presentations (HF + pneumonia) are common and require dual therapy.

Classic cardiogenic pulmonary edema vignette:

Targeted history (get within the first 5 minutes on CCS):

Risk-modifier history:

Symptom timing patterns:

Physical Exam Findings and Hemodynamic Assessment

— Tachypnea (RR >24), hypoxemia (SpO2 often <90% on room air)

— BP usually elevated or normal; hypotension = ominous (cardiogenic shock — different pathway)

— Tachycardia or new irregular rhythm (AFib)

— Bilateral inspiratory crackles, classically basilar progressing upward with severity ("rales to the apices" = severe)

— Wheezing ("cardiac asthma") from peribronchial edema — do not anchor on COPD

— Dullness to percussion at bases → pleural effusions (often right > left in HF)

— S3 gallop — highly specific for elevated LV filling pressures, LR+ ~4–6

— S4 → diastolic dysfunction, HTN, ischemia

— Holosystolic apical murmur → MR (functional or papillary muscle rupture if acute MI)

— Harsh systolic murmur radiating to carotids → AS (consider as ADHF trigger)

— Loud P2 → pulmonary HTN

— Warm & wet (well perfused, congested) → most common; diuresis + vasodilation

— Cold & wet (hypoperfused, congested) → inotropes + cautious diuresis, ICU

— Warm & dry → euvolemic, reconsider diagnosis

— Cold & dry → low output without congestion, inotropes/fluids carefully

— JVP >8 cm at 30°, hepatojugular reflux, peripheral edema, ascites

— Cool, mottled extremities, narrow pulse pressure → low cardiac output

— Prolonged cap refill, oliguria → hypoperfusion

Step 3 management: Document the Nohria-Stevenson profile in your CCS note within the first hour — it changes the order set. A "cold and wet" patient gets a dobutamine or milrinone order and an early ICU disposition, not just escalating furosemide. Repeat the perfusion assessment q1–2h after each intervention to capture trajectory.

Vital sign pattern in cardiogenic pulmonary edema:

Pulmonary exam:

Cardiac exam:

Volume/perfusion 2×2 (Stevenson/Nohria classification) — drives therapy:

Extremities/JVP:

Diagnostic Workup — Initial Labs, Imaging, ECG, Biomarkers

— ECG STAT — within 10 minutes; rule out STEMI/NSTEMI as ADHF trigger, identify AFib with RVR, LVH, prior infarct

— Portable CXR — bedside, upright if tolerated

— CBC, BMP, magnesium, LFTs

— Troponin (high-sensitivity, repeat at 3h per institutional protocol)

— BNP or NT-proBNP

— Lactate (perfusion marker)

— VBG/ABG if respiratory distress severe

— Urinalysis (proteinuria in preeclampsia, infection)

— TSH (new HF workup)

— COVID/influenza/RSV PCR in season

— Blood and urine cultures if febrile or septic-appearing

— Cephalization of pulmonary vessels, Kerley B lines, peribronchial cuffing

— Bat-wing/butterfly perihilar opacities

— Cardiomegaly (cardiothoracic ratio >0.5)

— Bilateral pleural effusions (R>L)

— Key distinction: ARDS shows diffuse bilateral infiltrates without cardiomegaly, without effusions, without Kerley lines

— BNP <100 / NT-proBNP <300 → HF unlikely (NPV ~90%)

— BNP >400 / NT-proBNP age-adjusted (>450 if <50y, >900 if 50–75, >1800 if >75) → HF likely

— Caveats: ↑ in renal failure, age, AFib, PE, sepsis; ↓ in obesity (use lower cutoffs ~50% reduction)

— B-lines (≥3 per field bilaterally) = pulmonary edema

— Reduced LV ejection fraction, dilated IVC (>2.1 cm, <50% collapse) → volume overload

— Pericardial effusion, RV strain (PE)

CCS pearl: Order CXR, ECG, troponin, BNP, BMP as a single bundle at time 0. Reassess at 30 minutes with results review and re-examine the patient. If troponin positive and ischemic ECG changes → activate cath lab/cardiology consult immediately; do not wait for the second troponin.

On arrival order set (enter simultaneously):

CXR findings supporting cardiogenic pulmonary edema:

BNP interpretation:

POCUS (point-of-care ultrasound) — increasingly standard, very Step 3-friendly:

Diagnostic Workup — Advanced or Confirmatory Studies

— Indicated in all new-onset HF and in decompensations with unclear etiology

— Assesses LVEF, wall motion abnormalities, valvular disease, RV function, pericardial effusion, diastolic function, estimated PA pressures

— On CCS: order "echocardiogram, transthoracic" within first 24h; result typically returns same day inpatient

— TEE if endocarditis, mechanical valve dysfunction, or aortic dissection suspected

— CT pulmonary angiogram if PE is in the differential (pleuritic pain, hemoptysis, unilateral leg swelling, low/normal BNP with severe dyspnea)

— Coronary angiography if ACS-driven HF, new regional wall motion abnormality, or unexplained new HFrEF in patient with CAD risk factors

— Cardiac MRI for suspected myocarditis, infiltrative cardiomyopathy (amyloid, sarcoid), or unexplained HFrEF after standard workup

— Not routine; reserved for cardiogenic shock, mixed shock, refractory pulmonary edema, or pre-transplant evaluation

— Provides PCWP (>18 = pulmonary edema), CO, SVR, PVR

— HbA1c, lipid panel, iron studies (iron deficiency very common in HF and treatable)

— HIV (if risk factors), SPEP/UPEP and free light chains if amyloid suspected (low voltage on ECG + thick walls on echo)

— Ferritin, transferrin saturation — TSAT <20% or ferritin <100 → IV iron indication in HF

Board pearl: A patient with HFpEF (preserved EF) and low-voltage ECG with concentric LVH on echo should trigger workup for cardiac amyloidosis — order technetium pyrophosphate (PYP) scan and rule out light-chain disease with serum/urine immunofixation before stamping it as "hypertensive heart disease." Missing this is a Step 3-favored stem.

Key distinction: HFrEF (EF ≤40%) drives the GDMT pharmacology pathway (ARNI, β-blocker, MRA, SGLT2i); HFpEF (EF ≥50%) management centers on SGLT2i, diuretics, BP/AFib control, and treating specific etiologies.

Transthoracic echocardiogram (TTE):

When to escalate imaging:

Right heart catheterization (PA catheter / Swan-Ganz):

Additional labs in new HF workup (Day 1–2):

Stress testing: Not in the acute phase; consider outpatient after stabilization if ischemia possible but cath not pursued.

Risk Stratification and First-Line Management Logic

— Lasix (IV loop diuretic)

— Morphine — historically taught but now discouraged (associated with worse outcomes; do not order on CCS unless specific palliative indication)

— Nitrates (IV nitroglycerin for SBP >110)

— Oxygen (target SpO2 ≥92%; ≥88% if COPD)

— Positive pressure ventilation (NIPPV)

— Nasal cannula 2–6 L → if SpO2 <92% or RR >25 → BiPAP (e.g., 10/5, FiO2 titrated)

— NIPPV reduces intubation rates and mortality in cardiogenic pulmonary edema (Class I)

— Failure of NIPPV (worsening hypoxia, hypercapnia, AMS, hemodynamic instability) → intubate

— Hypertensive flash edema (SBP >160): aggressive IV nitroglycerin ± nitroprusside, NIPPV, modest diuresis — fluid is redistributed, not always grossly overloaded

— Normotensive volume overload: IV loop diuretic is cornerstone; nitrates if symptomatic

— Hypotensive (SBP <90) / cardiogenic shock: vasopressors (norepinephrine) + inotrope (dobutamine or milrinone), hold ACEi/ARB/β-blocker, ICU, consider mechanical circulatory support (IABP, Impella, VA-ECMO)

— Time 0: O2, BiPAP if needed, IV access, ECG, CXR, labs, furosemide 40 mg IV (or 2.5× home oral dose), NTG SL or IV drip if SBP >140

— Time 30 min: reassess SpO2, RR, BP, urine output; titrate NTG (start 10 mcg/min, up to 200)

— Time 1 h: urine output goal >100 mL/h; if inadequate → double furosemide dose IV

— Time 2–4 h: reassess clinical congestion; transition to scheduled IV BID/TID dosing or continuous furosemide infusion

CCS pearl: On the CCS interface, place a Foley catheter to track urine output strictly q1h in any patient receiving IV diuresis for pulmonary edema — this is the single most important monitoring parameter and graders look for it. Also order daily weights and strict I/Os.

Immediate stabilization framework (LMNOP mnemonic) for acute pulmonary edema:

Respiratory support stepwise (time 0–30 min):

Hemodynamic phenotype drives next steps:

CCS time-anchored order set:

Pharmacotherapy — First-Line Drug Regimen

— Furosemide IV 40 mg if diuretic-naïve, or 2–2.5× total daily home oral dose IV if chronic user

— Bolus q12h or continuous infusion (5–20 mg/h after loading) — DOSE-AHF trial: high-dose strategy → greater diuresis, transient ↑Cr, no mortality difference

— Alternatives: bumetanide 1 mg IV, torsemide 20 mg IV (better PO bioavailability for discharge)

— Goal: net negative 1–2 L/day, urine output >100–150 mL/h in first 6 h

— IV nitroglycerin 10–20 mcg/min, titrate to symptom relief and BP; max ~200 mcg/min — best for hypertensive pulmonary edema and ischemia

— Nitroprusside for severe HTN/afterload reduction; avoid in renal failure (cyanide/thiocyanate toxicity)

— Hold for SBP <90 or symptomatic hypotension

— Add thiazide-type: metolazone 2.5–5 mg PO 30 min before loop, or chlorothiazide 500 mg IV

— Add acetazolamide 500 mg IV daily (ADVOR trial — improved decongestion)

— Add SGLT2 inhibitor (empagliflozin 10 mg PO) — EMPULSE trial; safe and beneficial in acute HF once stabilized

— ARNI (sacubitril/valsartan) — preferred over ACEi (PIONEER-HF: in-hospital initiation safe and reduces NT-proBNP)

— β-blocker (carvedilol, metoprolol succinate, bisoprolol) — continue if already on it and not in shock; initiate after euvolemia

— MRA (spironolactone 25 mg, eplerenone) — if K <5 and eGFR >30

— SGLT2 inhibitor (dapagliflozin, empagliflozin) — regardless of diabetes status, EF reduced OR preserved

— NSAIDs, thiazolidinediones, most non-dihydropyridine CCBs (verapamil, diltiazem) in HFrEF

— Routine morphine (associated with ↑ICU admission, ↑mortality)

Step 3 management: Initiate all four pillars of HFrEF GDMT before discharge — this is repeatedly tested. Patients started on ARNI + β-blocker + MRA + SGLT2i during hospitalization have significantly better 30-day readmission and 1-year mortality outcomes. Document each as either "started," "uptitrated," or "contraindication noted."

Loop diuretics (cornerstone):

Vasodilators:

Adjuncts if loop diuresis inadequate (diuretic resistance):

GDMT initiation/continuation for HFrEF (start before discharge, even during admission once stable):

Avoid in ADHF:

Procedures and Invasive Management

— CPAP 8–12 cm H2O or BiPAP 10–15 / 5–8 with FiO2 titrated

— Reduces preload and afterload by ↑intrathoracic pressure, ↓work of breathing

— Class I indication for acute cardiogenic pulmonary edema with respiratory distress

— Contraindications: AMS, vomiting, facial trauma, hemodynamic instability requiring intubation

— Indications: NIPPV failure, persistent hypoxia (SpO2 <88% on max NIPPV), hypercapnia with acidosis, AMS, hemodynamic collapse

— Etomidate or ketamine preferred for induction (less hypotension); avoid propofol bolus in shock

— Lung-protective ventilation: TV 6 mL/kg IBW, PEEP 8–10

— Urgent (<2 h): STEMI, mechanical complications (papillary muscle rupture, VSR, free wall rupture)

— Early (<24 h): NSTEMI with HF, hemodynamic instability

— Elective: new HFrEF with CAD risk factors and no clear alternative etiology

— Intra-aortic balloon pump (IABP) — afterload reduction, modest CO support

— Impella (percutaneous LVAD) — higher flow

— VA-ECMO — biventricular failure or severe respiratory + cardiac failure

— Trigger: SCAI shock stage C or worse despite vasopressor + inotrope

— Reserved for diuretic-resistant volume overload despite combination diuretics; not first-line (CARRESS-HF showed no benefit and worse renal function vs stepped diuretic therapy)

— Acute severe MR from papillary muscle rupture → emergent mitral valve surgery

— Severe AS driving decompensation → TAVR or SAVR after stabilization

— Acute prosthetic valve thrombosis → thrombolysis or surgery

CCS pearl: Place a central venous catheter for vasopressor/inotrope administration when starting norepinephrine or dobutamine, and consider an arterial line for continuous BP monitoring in shock or on nitroprusside drip. Document procedure indication and consent in your CCS notes.

Noninvasive positive pressure ventilation (NIPPV) — first-line procedure:

Endotracheal intubation:

Cardiac catheterization:

Mechanical circulatory support (cardiogenic shock pathway):

Ultrafiltration:

Valve interventions:

Therapeutic thoracentesis if large symptomatic pleural effusion not responding to diuresis (rare in acute phase).

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of HFpEF, atrial fibrillation, polypharmacy

— More sensitive to diuretic-induced hypotension, AKI, electrolyte disturbances

— Start lower diuretic doses, reassess more frequently (q2h initially)

— Beers criteria: avoid first-generation antihistamines, anticholinergics, NSAIDs; use β-blockers cautiously with bradycardia/AV block

— Cognitive screening before discharge — adherence is a top readmission driver

— Frailty assessment (e.g., Clinical Frailty Scale) informs goals of care

— Diuretic resistance is common — often need higher loop doses (furosemide 80–160 mg IV) or transition to bumetanide/torsemide (better absorption)

— Add metolazone or acetazolamide for sequential nephron blockade

— Monitor K, Cr, bicarbonate q12–24h during active diuresis

— ACEi/ARB/ARNI: continue if eGFR >30 and K <5; expect mild Cr bump (≤30%) — do not stop reflexively

— MRA: avoid if eGFR <30 or K >5

— SGLT2i: now safe down to eGFR 20 (dapagliflozin, empagliflozin); benefits persist

— Avoid IV contrast unless essential; if needed, isotonic IV fluids pre/post

— Missed HD is the top precipitant — arrange urgent dialysis with ultrafiltration

— Diuretics largely ineffective if anuric

— Cautious volume removal to avoid intradialytic hypotension

— Ascites can mimic or coexist with HF congestion

— Albumin infusion + diuretics (furosemide + spironolactone in 40:100 mg ratio) if hepatic

— Avoid hepatotoxic medications; dose-adjust β-blockers

— Cirrhotic cardiomyopathy — consider when LV dysfunction develops in advanced liver disease

Board pearl: A 25–30% rise in creatinine during aggressive diuresis is acceptable and not a reason to stop diuretics if congestion persists — the patient is still wet and needs decongestion. Persistent congestion at discharge predicts readmission far more than transient AKI.

Step 3 management: In CKD with diuretic resistance, escalate by doubling the IV loop dose, then add thiazide 30 min before, then consider continuous infusion, then acetazolamide, before invoking ultrafiltration.

Elderly (≥75 years):

Chronic kidney disease (eGFR <60):

End-stage renal disease on hemodialysis:

Hepatic impairment / cirrhosis:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Peripartum cardiomyopathy (PPCM): new HFrEF in last month of pregnancy or within 5 months postpartum; presents with dyspnea, orthopnea, edema — easily mistaken for normal pregnancy symptoms

— Diagnosis: echo showing LVEF <45% without alternative cause

— Acute management: O2, NIPPV, furosemide IV (safe), hydralazine + nitrates (safe alternatives to ACEi/ARB which are contraindicated in pregnancy)

— β-blockers: metoprolol or labetalol preferred (avoid atenolol — IUGR)

— Bromocriptine has been studied for PPCM — adjunctive, controversial

— Anticoagulation if EF <35% (high thromboembolism risk)

— Delivery planning: multidisciplinary (OB, cardiology, anesthesia); vaginal delivery preferred if stable

— Edema from increased capillary permeability + HTN + iatrogenic fluids

— Treat with magnesium sulfate, antihypertensives (labetalol, hydralazine, nifedipine), cautious diuresis, delivery as definitive therapy

— Causes: congenital heart disease, myocarditis, dilated cardiomyopathy

— Avoid diuretic overdiuresis — small patients decompensate quickly

— Consider myocarditis (viral, post-COVID), HCM (sudden death risk), arrhythmogenic cardiomyopathy, anomalous coronary, substance use (cocaine, anabolic steroids)

— Cardiac MRI and genetic testing often indicated

— Anthracycline cardiomyopathy (doxorubicin, daunorubicin), trastuzumab-induced (often reversible), immune checkpoint inhibitor myocarditis — high mortality, needs steroids

— Cocaine/methamphetamine → catecholamine surge, flash edema; avoid β-blocker monotherapy in acute cocaine intoxication (use benzodiazepines + nitrates first)

— Alcoholic cardiomyopathy — abstinence is therapy

Board pearl: A postpartum woman with new dyspnea and orthopnea must be evaluated for peripartum cardiomyopathy with urgent echocardiogram — do not attribute symptoms to postpartum fatigue. Diagnostic delay increases mortality.

Pregnancy and peripartum:

Preeclampsia/eclampsia with pulmonary edema:

Pediatric considerations (rare in adult CCS but tested in cross-over stems):

Athletes/young adults with new HF:

Immunocompromised/post-chemotherapy:

Substance-related:

Complications and Adverse Outcomes

— Cardiogenic shock progression — SBP <90, end-organ hypoperfusion, lactate >2 → ICU, inotropes, MCS

— Respiratory failure requiring intubation — 5–10% despite NIPPV

— Acute kidney injury (cardiorenal syndrome type 1) — rising Cr during diuresis; manage by continuing decongestion if patient still wet, holding nephrotoxins

— Electrolyte derangements: hypokalemia (K <3.5), hypomagnesemia, hyponatremia (poor prognostic marker), metabolic alkalosis from contraction

— Arrhythmias: new AFib (precipitant or consequence), nonsustained VT, AV block from β-blocker overdose

— NIPPV: gastric distention, aspiration, claustrophobia, pressure ulcers

— Intubation: post-intubation hypotension (preload drop with PPV)

— Diuretic-induced: ototoxicity (rapid high-dose IV furosemide), gout flare

— ACEi/ARB/ARNI: hyperkalemia, angioedema, cough (ACEi), worsening Cr

— MRA: hyperkalemia, gynecomastia (spironolactone)

— SGLT2i: euglycemic DKA, genital mycotic infections, volume depletion

— Nitrates: hypotension, headache, contraindicated within 24–48 h of PDE5 inhibitor (sildenafil, tadalafil) — always ask

— 30-day readmission rate ~20% — among the highest of any condition; targeted by CMS penalties

— Progressive LV remodeling without GDMT

— Sudden cardiac death — risk-stratify for ICD (EF ≤35% despite ≥3 months of GDMT, NYHA II–III)

— Cardiac cachexia, sarcopenia, depression

— Anchoring on ADHF when pneumonia or PE coexists — miss leads to deterioration

— Diuresing a right-sided MI (RV infarct) — causes profound hypotension; treat with fluids, not diuresis

Key distinction: Cardiorenal syndrome type 1 (acute HF → AKI) is managed by continued decongestion, not by holding diuretics. Stopping diuresis in a wet patient with a rising Cr worsens outcomes. The error tested on Step 3 is reflexive diuretic discontinuation when Cr bumps from 1.2 to 1.6.

Acute complications during initial management:

Procedure-related:

Pharmacologic adverse events:

Subacute/chronic complications:

Diagnostic complications:

When to Escalate Care — ICU, Consult, and Disposition

— Respiratory failure requiring intubation or persistent NIPPV requirement

— Cardiogenic shock (SBP <90, lactate >2, oliguria, AMS) or need for vasopressors/inotropes

— Hemodynamically unstable arrhythmia (VT, complete heart block, AFib with RVR not responding to rate control)

— STEMI or NSTEMI with hemodynamic instability

— Mechanical complications of MI (papillary muscle rupture, VSR, free wall rupture)

— Need for arterial line, PA catheter, IABP/Impella/ECMO

— Stable on IV diuresis without vasoactive drips

— Heart rate and rhythm monitoring needed

— Moderate respiratory distress on supplemental O2 (not NIPPV)

— Hemodynamically stable, normal mental status

— Tolerating PO or scheduled IV diuretics

— No active ischemia or arrhythmia

— Cardiology: all new HF diagnoses, all decompensations requiring inotropes, new arrhythmias, suspected ACS, valvular disease

— Interventional cardiology: STEMI, NSTEMI with refractory symptoms, mechanical complications

— Cardiothoracic surgery: acute MR, VSR, severe AS for SAVR, advanced HF for LVAD/transplant evaluation

— Nephrology: dialysis-dependent volume overload, refractory cardiorenal syndrome

— Palliative care: NYHA IV refractory to optimal therapy, frequent readmissions, considering hospice

— Time 0–1 h: stabilize, diagnose; if shock → ICU, vasopressors, cardiology

— Time 2–6 h: reassess response; if worsening hypoxia/hypotension → escalate ventilation, ICU

— Day 1: echocardiogram, GDMT initiation if HFrEF, telemetry

— Day 2–3: transition IV→PO diuretics, uptitrate GDMT

— Day 3–5: discharge planning when euvolemic on stable oral regimen for 24 h

CCS pearl: Discharge criteria on CCS — 24 hours on oral diuretic with stable weight, BUN/Cr, and BP, all GDMT pillars initiated or contraindication documented, and follow-up appointment within 7–14 days scheduled. Premature discharge is a common CCS scoring deduction.

ICU admission criteria:

Step-down/telemetry unit:

General medical floor:

Consultations:

CCS time-anchored escalation:

Key Differentials — Same-Category (Cardiac) Causes

— Ischemic chest pain or anginal equivalent + new ST changes + troponin elevation

— Treat HF and pursue urgent revascularization; Killip class III (pulmonary edema) is high mortality

— Papillary muscle rupture → acute severe MR, flash pulmonary edema, new loud holosystolic murmur (or soft due to equalized pressures); echo confirms; emergent surgery

— Ventricular septal rupture → harsh new murmur, biventricular failure, RV volume overload

— Free wall rupture → tamponade, PEA arrest

— Most common; identify precipitant (diet, meds, AFib, ischemia, infection)

— Critical aortic stenosis with rapid HR or volume → flash pulmonary edema

— Acute mitral regurgitation (endocarditis, papillary muscle, chordae rupture)

— Prosthetic valve thrombosis or dehiscence

— SBP often >200; usually preserved EF with severe diastolic dysfunction

— Management: IV nitroglycerin or clevidipine/nicardipine, modest diuresis, NIPPV; lower MAP by 20–25% in first hour

— Persistent AFib with RVR, atrial flutter, or chronic SVT → LV dysfunction; rate or rhythm control reverses it

— Bilateral crackles can occur if pulmonary venous pressure rises; usually with hypotension, JVD, pulsus paradoxus, muffled heart sounds — echo, pericardiocentesis

— Right-predominant failure, ascites, Kussmaul sign, pericardial knock

— Younger patient, recent viral illness or vaccination, troponin elevation, diffuse hypokinesis on echo, MRI shows myocardial edema

— Postmenopausal woman, emotional/physical stressor, apical ballooning on echo, transient LV dysfunction

Board pearl: New holosystolic murmur + acute pulmonary edema 2–7 days after MI → papillary muscle rupture until proven otherwise. Order STAT echocardiogram and call CT surgery; medical therapy alone has >50% mortality.

Acute coronary syndrome (STEMI/NSTEMI) with HF:

Mechanical complications of MI (typically 2–7 days post-MI):

Acute decompensation of chronic HFrEF or HFpEF:

Severe valvular disease:

Hypertensive emergency with pulmonary edema (flash edema):

Tachyarrhythmia-induced cardiomyopathy:

Cardiac tamponade:

Pericardial constriction:

Myocarditis:

Stress cardiomyopathy (Takotsubo):

Key Differentials — Other-Category Causes of Bilateral Crackles + Dyspnea

— Fever, cough, productive sputum, focal or multifocal consolidation on CXR

— Procalcitonin elevated; BNP low or modestly elevated

— Treat with antibiotics per CAP/HAP guidelines + supportive care

— Berlin criteria: bilateral infiltrates, PaO2/FiO2 ≤300, not fully explained by cardiac failure, within 7 days of insult

— Key distinction: No cardiomegaly, no Kerley B lines, BNP usually <100, PCWP ≤18 (if measured); driven by sepsis, pancreatitis, trauma, transfusion, aspiration

— Management: low tidal volume ventilation (6 mL/kg IBW), PEEP titration, prone positioning, conservative fluids

— Acute dyspnea, pleuritic pain, tachycardia, hypoxia, clear lungs or focal findings, normal-to-mildly elevated BNP/troponin

— D-dimer (negative rules out in low-pretest patients), CTPA confirms

— Anticoagulation; thrombolysis if massive

— Within 6 h of transfusion; TACO = volume overload (high BNP, responds to diuresis), TRALI = noncardiogenic (low BNP, supportive care, no diuresis)

— Hemoptysis, dropping hemoglobin, bilateral infiltrates; vasculitis (ANCA), Goodpasture, SLE

— Rapidly progressive hypoxia, GGO + reticulation on CT; consider steroids

— History of obstructive disease; wheeze prominent, expiratory phase prolonged

— But cardiac asthma can mimic — BNP and POCUS help differentiate

— Ascent above 2500 m, dry cough then pink frothy sputum; treatment: descent, O2, nifedipine

— Recent TBI, SAH, seizure; sympathetic surge mechanism

— Opioid overdose (heroin, fentanyl), salicylates, chemotherapy (cytarabine, gemcitabine)

— Urticaria, hypotension, bronchospasm; epinephrine IM, not diuretics

Key distinction: BNP <100 + bilateral infiltrates + clinical sepsis → think ARDS or pneumonia, not ADHF. Conversely, BNP >400 + cardiomegaly + Kerley lines + S3 → ADHF, even if a low-grade fever is present.

Pneumonia (community-acquired, hospital-acquired, aspiration):

Acute respiratory distress syndrome (ARDS):

Pulmonary embolism:

TRALI / TACO:

Diffuse alveolar hemorrhage:

Acute interstitial pneumonia / acute exacerbation of ILF:

Asthma/COPD exacerbation with wheeze and rhonchi mistaken for crackles:

High-altitude pulmonary edema (HAPE):

Neurogenic pulmonary edema:

Drug-induced pulmonary edema:

Anaphylaxis:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— ARNI (sacubitril/valsartan 24/26 mg BID start, titrate to 97/103 BID) — or ACEi/ARB if ARNI not feasible

— β-blocker (carvedilol 3.125 mg BID, metoprolol succinate 12.5–25 mg daily, bisoprolol 1.25 mg daily) — start low, double q2 weeks

— MRA (spironolactone 25 mg daily or eplerenone 25 mg daily) — if eGFR >30, K <5

— SGLT2i (dapagliflozin 10 mg or empagliflozin 10 mg daily) — regardless of diabetes

— SGLT2i (empagliflozin, dapagliflozin) — Class I after EMPEROR-Preserved, DELIVER

— Loop diuretic for congestion

— Treat HTN aggressively (goal <130/80), AFib rate/rhythm control, treat OSA, weight loss

— MRA can be considered (TOPCAT — modest benefit, hyperkalemia risk)

— Statin if ASCVD or risk-equivalent

— Antiplatelets/anticoagulation as indicated (ASCVD, AFib — anticoagulate per CHA2DS2-VASc)

— Iron repletion: IV iron (ferric carboxymaltose) if TSAT <20% or ferritin <100 (or 100–300 with TSAT <20%) — improves symptoms and reduces readmission (AFFIRM-AHF)

— Vaccinations: annual influenza, pneumococcal (PCV15/PCV20 then PPSV23), COVID-19, RSV (≥60), Tdap

— ICD/CRT evaluation: at ≥90 days of optimal GDMT with persistent EF ≤35% (ICD), QRS ≥150 ms with LBBB (CRT)

— Sodium <2–3 g/day, fluid restriction 1.5–2 L/day if hyponatremic or severe HF

— Daily weight monitoring — call provider for >2 lb in 1 day or 5 lb in 1 week

— Cardiac rehabilitation — Class I for stable HFrEF

— Tobacco cessation, alcohol moderation, drug cessation

— Sleep study if OSA suspected

— Medication adherence, low-salt diet teaching, weight log, action plan for symptoms

Step 3 management: Patients discharged with all four GDMT pillars initiated have ~70% lower 1-year mortality vs none, even at submaximal doses (STRONG-HF trial — rapid uptitration strategy). Document each pillar status at discharge.

HFrEF discharge medication pillars (all four if tolerated):

HFpEF discharge medications:

Additional secondary prevention:

Lifestyle:

Patient education:

Follow-Up, Monitoring, and Rehab/Counseling

— Within 7 days: clinic visit with primary care or HF clinic — strongly reduces 30-day readmissions

— 2 weeks: BMP to check K and Cr after diuretic/ACEi/MRA changes

— 2–4 weeks: GDMT uptitration visit

— 3 months: repeat echocardiogram if HFrEF on GDMT — assess for EF recovery and ICD/CRT candidacy

— 6–12 months: ongoing GDMT optimization, ICD/CRT if criteria persist

— Weight, BP, HR, JVP, edema, symptoms (NYHA class)

— BMP (K, Cr, Na), BNP/NT-proBNP trending (optional)

— Medication adherence and side effects

— Iron studies q6 months in HFrEF

— Class I indication for stable HFrEF (HF-ACTION trial — improved functional capacity, QoL, modest mortality benefit)

— Typically 36 sessions over 12 weeks, exercise + education + risk factor modification

— Now also indicated for HFpEF per recent updates

— Daily weights with written log; call if >2 lb/day or >5 lb/week gain

— Sodium <2 g/day; written diet plan, dietitian referral

— Fluid restriction 1.5–2 L/day in advanced HF or hyponatremia

— Medication review at every visit; ask about NSAIDs, OTC cold meds (decongestants worsen HF)

— Symptom recognition: dyspnea, orthopnea, lower extremity swelling — early action prevents readmission

— Advance care planning discussions, especially NYHA III–IV

— CardioMEMS (PA pressure sensor) — Class IIb in NYHA II–III with prior admission

— Telephonic/digital scales with provider alerts

— Reduces readmissions when paired with multidisciplinary HF program

CCS pearl: On the CCS interface at discharge, explicitly order:

— "Follow-up with cardiology in 7 days"

— "Follow-up with primary care in 7 days"

— "Repeat BMP in 1 week"

— "Cardiac rehab referral"

— "Daily weight log"

— "Low-sodium diet, 2 g/day"

— "Repeat TTE in 3 months"

Skipping these is the most common CCS deduction in HF cases.

Post-discharge follow-up cadence:

Monitoring parameters at each visit:

Cardiac rehabilitation:

Counseling priorities:

Remote monitoring:

Ethical, Legal, and Patient Safety Considerations

— NYHA IV with frequent admissions, refractory symptoms despite optimal therapy → discuss prognosis, palliative care, hospice

— Median survival in NYHA IV is approximately 6–12 months; honest disclosure is required for informed decision-making

— Advance directives, POLST/MOLST, healthcare proxy designation should be addressed at every admission

— Deactivation of ICD at end of life is ethically and legally permissible (parallel to withdrawing other life-sustaining therapy); not euthanasia

— Have explicit conversation when transitioning to comfort care — unaddressed ICDs cause distressing shocks

— Document patient/surrogate consent for deactivation

— Hospital-to-home transition is the highest readmission risk window in medicine

— Medication reconciliation at admission, transfer, and discharge — required by Joint Commission

— Discharge summary to PCP within 24–48 h, written discharge instructions at appropriate health-literacy level (6th grade)

— Teach-back method to confirm understanding

— Polypharmacy risk: average HF patient leaves on 6–10 medications; pharmacist review reduces errors

— Acute hypoxia, hypercapnia, hypoperfusion can impair capacity transiently → reassess before consenting to procedures

— In incapacitated patients, use surrogate decision-makers per state hierarchy; if none, ethics consult

— Driving restrictions after ICD shock or syncope — per state law (typically 6 months post-event); document counseling

— Report impaired drivers if mandated by state

— Suspected elder abuse or neglect contributing to medication nonadherence → adult protective services

— Underrepresented minorities have higher HF mortality and lower GDMT prescription rates — actively address disparities

— Address insurance access for SGLT2i, ARNI (cost barriers contribute to nonadherence)

— VTE prophylaxis during admission (enoxaparin 40 mg SC daily unless contraindicated)

— Fall precautions in elderly diuresing patients (orthostasis risk)

— Glycemic monitoring with SGLT2i — euglycemic DKA

Board pearl: A patient with end-stage HF and a functioning ICD who chooses comfort care has the right to request ICD deactivation; physicians cannot ethically refuse on grounds of "withdrawing therapy." A device representative can deactivate at bedside, or a magnet can be applied as a temporary measure.

Goals-of-care discussions in advanced HF:

ICD-specific ethical issues:

Transitions of care (high-risk Step 3 topic):

Decision-making capacity:

Mandatory reporting and safety:

Health-system equity:

Patient safety bundles:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When the question stem mentions an older man with HFpEF, bilateral carpal tunnel surgeries, and aortic stenosis, think transthyretin (ATTR) cardiac amyloidosis — order technetium pyrophosphate scintigraphy and consider tafamidis therapy.

Crackles + S3 + JVD + bilateral pleural effusions → ADHF, virtually pathognomonic

Flash pulmonary edema with hypertension and normal EF → think HFpEF, severe HTN, ± renal artery stenosis (especially recurrent flash edema with ACEi-induced AKI) — workup with renal Doppler/MRA

Bibasilar crackles + low BNP + bilateral infiltrates + clear sepsis → ARDS, not ADHF

Postpartum dyspnea with new HFrEF → peripartum cardiomyopathy until proven otherwise

MI 3–5 days ago + new holosystolic murmur + flash edema → papillary muscle rupture

Low-voltage ECG + thick LV walls + HFpEF + bilateral CTS or neuropathy in older man → cardiac amyloidosis (TTR or AL); confirm with PYP scan + light-chain workup

Recurrent ADHF in dialysis patient → missed HD session, dietary indiscretion

Hyponatremia in HF → poor prognostic marker (advanced disease, neurohormonal activation); treat HF not Na directly

Iron deficiency in HF (TSAT <20% or ferritin <100) — IV iron improves outcomes regardless of anemia

NIPPV (BiPAP/CPAP) reduces intubation and mortality in cardiogenic pulmonary edema

Morphine in ADHF → associated with worse outcomes; avoid

Loop diuretic dosing in chronic users: IV dose ≥ 2.5× total daily oral dose

DOSE-AHF: high-dose IV diuretic strategy yields better symptom relief with transient Cr rise but no mortality difference

EMPULSE / EMPEROR / DAPA-HF / DELIVER: SGLT2i benefit across the EF spectrum, including acutely

PIONEER-HF: in-hospital ARNI initiation safe and lowers NT-proBNP and rehospitalization

STRONG-HF: rapid GDMT uptitration in first 2 weeks post-discharge → ↓180-day readmission/death

HF readmission rate ~20% at 30 days — CMS-tracked quality metric

Echo in 3 months to reassess EF after GDMT — ICD candidacy if EF still ≤35%

CRT indication: EF ≤35%, NYHA II–IV, LBBB with QRS ≥150 ms, sinus rhythm

POCUS B-lines (≥3/field bilaterally) — sensitive for pulmonary edema

Cardiac asthma: wheezing in HF; do not anchor on COPD without considering HF

Sildenafil + nitrates → contraindicated (severe hypotension); always ask before NTG

RV infarct → preload-dependent; diuresis is harmful, give fluids instead

CardioMEMS PA pressure monitoring reduces HF admissions in select patients

AFFIRM-AHF: IV ferric carboxymaltose post-decompensation reduces readmissions

Board Question Stem Patterns

— 70-year-old with EF 30%, hospitalized 3 months ago, presents with 5 days of worsening dyspnea, orthopnea, 8-lb weight gain, JVP 12 cm, bibasilar crackles, S3, 2+ pitting edema. BNP 1800. CXR shows cephalization and Kerley B lines.

— Best initial step: IV furosemide (2.5× home dose) + NIPPV if hypoxic + IV NTG if hypertensive

— Discharge meds: ARNI + carvedilol + spironolactone + dapagliflozin + loop diuretic

— 60-year-old with HTN presents with sudden severe dyspnea, BP 220/115, RR 32, SpO2 84% RA, bilateral crackles to mid-lung fields.

— Best initial step: NIPPV + IV nitroglycerin + modest IV furosemide

— Workup: rule out ACS, consider renal Doppler for renal artery stenosis if recurrent

— Patient with prior MI presents with hypotension (SBP 78), cool extremities, lactate 4.5, oliguria, bilateral crackles.

— Answer: Norepinephrine + dobutamine, ICU, echocardiogram, cardiac catheterization; do not start ACEi/ARB or aggressive diuresis until perfusion restored

— 5 days post-anterior MI, new harsh holosystolic murmur, acute pulmonary edema, BP 90/60.

— Answer: Emergent echocardiogram → papillary muscle rupture or VSR → CT surgery consult, IABP bridge

— Septic patient with bilateral infiltrates, PaO2/FiO2 180, BNP 80, normal-sized heart on CXR.

— Answer: ARDS — low tidal volume ventilation, conservative fluids, treat source; not diuretics first-line

— 2 weeks postpartum, dyspnea, orthopnea, EF 25%.

— Answer: PPCM; furosemide, hydralazine + nitrate (avoid ACEi if breastfeeding initially — actually enalapril/captopril considered compatible postpartum), metoprolol, anticoagulate if EF <35%

— 75-year-old man with HFpEF, low ECG voltage, septal thickness 18 mm, bilateral carpal tunnel history.

— Answer: Technetium PYP scan + serum/urine immunofixation, free light chains

— End-stage HF patient on hospice requesting no more shocks.

— Answer: Deactivate ICD; ethically permissible, document consent

— Patient now euvolemic on PO furosemide for 24 h.

— Answer: Initiate or confirm all four GDMT pillars, schedule 7-day follow-up, cardiac rehab referral, repeat echo in 3 months

Step 3 management: The most-tested wrong answers are (1) giving fluids to a hypotensive pulmonary edema patient before defining the etiology (RV infarct vs cardiogenic shock), (2) stopping diuretics for mild Cr rise during decongestion, (3) giving β-blocker to a patient in active cardiogenic shock, and (4) discharging without initiating GDMT.

Stem 1 — Classic ADHF:

Stem 2 — Flash pulmonary edema:

Stem 3 — ADHF with cardiogenic shock:

Stem 4 — Post-MI mechanical complication:

Stem 5 — ARDS mimic:

Stem 6 — Peripartum cardiomyopathy:

Stem 7 — Cardiac amyloidosis:

Stem 8 — ICD deactivation:

Stem 9 — Discharge readiness:

One-Line Recap

Acute shortness of breath with bilateral crackles in the ED is acute decompensated heart failure with cardiogenic pulmonary edema until proven otherwise — stabilize with oxygen and NIPPV, define hemodynamic phenotype, deliver IV loop diuretic and IV nitrates for hypertensive/volume-overloaded patients, escalate to vasopressors/inotropes for cardiogenic shock, work up the precipitant (ACS, arrhythmia, nonadherence, valvular disease), initiate all four GDMT pillars before discharge for HFrEF, and schedule a 7-day follow-up to break the readmission cycle.

High-yield recap bullets:

Board pearl: The CCS rubric rewards parallel ordering (stabilization + diagnostics + therapy), time-anchored reassessments (q15min initially, q1h after stabilization), and structured discharge planning with all four GDMT pillars and 7-day follow-up explicitly entered — these are the single biggest swing factors in scoring an acute pulmonary edema case.

First 30 minutes: O2, NIPPV if respiratory distress, IV access, ECG <10 min, CXR, BNP, troponin, BMP, furosemide IV (2.5× home dose), IV NTG if SBP >140; Foley for strict urine output ≥100 mL/h

Phenotype-driven therapy: hypertensive flash edema → vasodilator-heavy; volume overload → diuretic-heavy; cardiogenic shock → norepinephrine + dobutamine, ICU, MCS consideration; avoid morphine, NSAIDs, fluids in a wet patient

HFrEF GDMT four pillars before discharge: ARNI + β-blocker + MRA + SGLT2i; HFpEF → SGLT2i, diuretics, BP/AFib control; iron repletion with IV ferric carboxymaltose if TSAT <20% or ferritin <100

Disposition and follow-up: discharge only after 24 h euvolemic on oral diuretic; clinic in 7 days, BMP in 1–2 weeks, repeat echo in 3 months, cardiac rehab referral, daily weight log, sodium <2 g/day; reassess for ICD/CRT at 90 days of optimal GDMT

Don't miss differentials: ARDS, pneumonia, PE, papillary muscle rupture, peripartum cardiomyopathy, cardiac amyloidosis, renal artery stenosis (recurrent flash edema), and RV infarct (preload-dependent — give fluids, not diuretics)